Clinical trials: Non-Small Cell Lung
Non-squamous Non-small Cell Lung Cancer
Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
The objective of this study is to assess the similarity between QL1101 and Avastin® respectively combined with chemotherapy in terms of efficacy and safety in patients with non-squamous non-small cell lung cancer.
- Trial name
- NCT03169335
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 535 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
- Trial name
- NCT01209650
- Testing
- BIBW 2992
- Where
- Australia
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Carcinoma
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by…
- Trial name
- SELINE (NCT00608868)
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Gastric Cancer, Bladder Cancer
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.
- Conditions
- Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer, Cholangiocarcinoma
- Trial name
- NCT04149691
- Testing
- CPL304110
- Where
- 7 sites in Poland
- Volunteers
- 37 people
- Sponsor
- Celon Pharma SA
Advanced Non Small Cell Lung Cancer
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
This pilot study uses [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors.
- Trial name
- NCT06107374
- Testing
- [18F]F-AraG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CellSight Technologies, Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this clinical trial is to compare Utidelone with Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously failed platinum-containing chemotherapy regimens.
- Trial name
- NCT05673590
- Testing
- Utidelone Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Metastatic NSCLC
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status)…
- Trial name
- NCT06159790
- Testing
- GME751, Keytruda-EU
- Where
- 62 sites in United States, Bosnia and Herzegovina and 14 more
- Volunteers
- 218 people
- Sponsor
- Sandoz
Carcinoma, Non-Small-Cell Lung
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without…
- Trial name
- NCT05487391
- Testing
- QL1706 injection, Vinorelbine Tartrate, Paclitaxel
- Where
- China
- Volunteers
- 632 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Non-Small-Cell Lung Cancer
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999.
- Trial name
- NCT00491699
- Testing
- XL999
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Symphony Evolution, Inc.
Non-Small Cell Lung Cancer
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced non-small cell lung cancer.
- Trial name
- NCT07623356
- Testing
- AK138D1, Ivonescimab, Carboplatin
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Akeso
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Non-squamous Non-small Cell Lung Cancer
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
This trial is a registrational phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with first-line treatment of HER2-mutant advanced or metastatic non-squamous…
- Trial name
- NCT07178795
- Testing
- BL-M07D1, Pembrolizumab, Pemetrexed
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
NSCLC (Non-small-cell Lung Cancer)
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)
- Trial name
- NCT05118334
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Nonsmall Cell Lung Cancer
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients…
- Trial name
- NCT06147570
- Testing
- HS-10365 capsules
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
- Trial name
- NCT04484142
- Testing
- DS-1062a
- Where
- 84 sites in United States, France and 8 more
- Volunteers
- 137 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
To explore the non-inferiority of a cfDNA amplicon-based liquid biopsy technology vs. standard of care tissue biopsy-based NGS in detecting guideline- recommended biomarkers in patients with metastatic non-squamous Non-small Cell…
- Trial name
- LIQUIK (NCT04703153)
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Lucence Health Inc.
Non Small Cell Lung Cancer
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the…
- Trial name
- NCT04495153
- Testing
- Aglatimagene besadenovec
- Where
- 14 sites in United States
- Volunteers
- 90 people
- Sponsor
- Candel Therapeutics, Inc.
Non-Small Cell Lung Cancer
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
- Trial name
- CheckMate 907 (NCT03090737)
- Testing
- Nivolumab
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 129 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
- Trial name
- NCT05879822
- Testing
- INCB099280
- Where
- 54 sites in Brazil, China and 7 more
- Volunteers
- 73 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.